thought call
thought merck result solid in-lin revenu ep beat
look longer term point sever favor fundament trend
make stock much attract view exampl keytruda
contribut increas revenu good thing given
durability/defens keytruda drive acceler total revenu growth
diabet contribut major investor worri
diminish could revenu loe period get
lung dynam wide discuss see
perspect investor/ oncologist feedback mrk/bmi
highlight kol nsclc oncologist call increment
contribut could meaning multi-year cadenc us
eu jpn row segment vaccin oncolog non i/o
anim health look healthi revenu diversifi clearli focu
keytruda base i/o upsid potenti contribut without need deal
drive growth like merck profil support ow rate pt
busi develop bd unlik transform get sens
manag prefer smaller scale bd form strateg allianc in-licens
deal versu transform acquisit good thing merck given mix
deal track record bd larg deal mantra similar peer note valuat
becom unreason suggest measur approach
model chang given recent trend commentari updat revenu
forecast
respect margin increas keytruda also updat opex
assumpt result revis non-gaap ep
page detail
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ merck like
continu take share lung back
posit data addit
view perhap first-lin lung
market share grab us support
ow rate
faster uptak keytruda nsclc i/o
combin data acceler develop
preserv market share de-risk pipelin
posit pipelin data could put upward bia
consensu estim re-rat stock
continu weak core brand like remicad
januvia coupl faster share declin
keytruda pipelin setback could depress
revenu estim forward multipl
given recent trend commentari updat revenu forecast
respect also
updat opex assumpt result revis non-gaap ep
figur detail
million except per share itemspriorcurrentchg chg incom net item net ep ep ep ep outstand outstand analysispriorcurrentchg chg bp gross tax growthpriorcurrentchg chg million except per share itemspriorcurrentchg chg incom net item net ep ep ep ep outstand outstand analysispriorcurrentchg chg bp gross tax growthpriorcurrentchg chg barclay merck co
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
author contribut research report research analyst unless otherwis indic
public date top report reflect local time report produc may differ releas date provid
gmt
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
procedur pleas
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis barclay research depart
oper independ absa research depart absa research produc absa bank limit act corpor
invest bank divis part barclay africa group limit affili invest bank barclay bank plc elig
client may receiv research report research depart may reach differ conclus may contain differ
conflict forecast recommend trade idea
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
